S.Cooper

60 posts

S.Cooper banner
S.Cooper

S.Cooper

@DrSACooper

Oncology, sourdough bread, hopeful PhD. possibly wrong order. views own

Katılım Eylül 2012
125 Takip Edilen68 Takipçiler
S.Cooper retweetledi
Neil Newman
Neil Newman@nbn426·
So impressive what can be offered to patients with RCC!
Shankar Siva@_ShankarSiva

#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm 1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months. 2) 100% Cancer-Specific Survival 3) Grade 3 AEs remain at 10%

English
0
4
11
1.3K
S.Cooper retweetledi
Himanshu Nagar
Himanshu Nagar@HimanshuNagarMD·
@TylerSbrt Will be interesting to see RSI integration into Destination 2 😉
English
1
2
2
264
S.Cooper retweetledi
Giulia Marvaso
Giulia Marvaso@GiuliaMarvaso84·
One of the standout talks of #ESTRO2026 👏 'A lot to be proud of' @alison_tree brilliantly highlighted how modern #RadOnc in #PCa is evolving beyond technology alone , with increasing focus on continenze, sexual function and QoL alongside outstanding cancer control!
Giulia Marvaso tweet mediaGiulia Marvaso tweet mediaGiulia Marvaso tweet mediaGiulia Marvaso tweet media
English
3
21
59
12.8K
S.Cooper retweetledi
Alison Tree 💙
Alison Tree 💙@alison_tree·
Great presentation from @DrSACooper on the DESTINATION 1 trial - dose escalation to GTV and simultaneously de-escalating rest of gland appears to have similar adverse events to PACE B. Thanks to collaborators @MOMENTUM_study @dr_vesi @royalmarsdenNHS Uulke van der Heide
Alison Tree 💙 tweet mediaAlison Tree 💙 tweet mediaAlison Tree 💙 tweet mediaAlison Tree 💙 tweet media
English
0
15
31
1.5K
S.Cooper retweetledi
Alison Tree 💙
Alison Tree 💙@alison_tree·
@TylerSbrt @ESTRO_RT underlining the importance of training and optimising imaging for boost contouring. Great talk 👏
Alison Tree 💙 tweet media
English
0
6
24
2.4K
S.Cooper retweetledi
Alison Tree 💙
Alison Tree 💙@alison_tree·
Great presentation by @DrSACooper @ESTRO_RT showing low adverse events in both 5 and 2 fraction MRI-guided adaptive radiotherapy (HERMES trial), with minimal impact on quality of life in both arms.
Alison Tree 💙 tweet mediaAlison Tree 💙 tweet media
English
2
11
32
2.7K
S.Cooper retweetledi
Piet Ost
Piet Ost@piet_ost·
@juliarmurray winning over the audience for treating the primary in metastatic PCa. Taking out the walnut from your shoe during a 5k run. I would even take it further: de novo mHSPC is a marathon now for our patients, so taking out the walnut makes even more sense. #ESTRO2026
Piet Ost tweet media
English
3
15
58
2.6K
S.Cooper retweetledi
Piet Ost
Piet Ost@piet_ost·
🔬 PEACE 2 phase III: Adding pelvic RT to prostate RT + 3y ADT in very high-risk localized prostate cancer did NOT improve bPFS, MFS, CSS or OS. Borderline cPFS signal (HR 0.81, p=0.09). No added AEs. @PBlanchard_MD #ESTRO2026. @VedangMurthy what now?
Piet Ost tweet mediaPiet Ost tweet mediaPiet Ost tweet media
English
6
60
137
10.1K
S.Cooper
S.Cooper@DrSACooper·
Enormous thanks to co-authors @DylanYamabe @Xristodouleas @pakolias Sophie Alexander, Francis Casey, Mathijs G Dassen, Veronica Dell’acqua, Alex Dunlop, Trina Herbert, Pavlos Kolias, Adam Mitchell, Floris J Pos, Rosalyne Westley
English
0
0
2
238
S.Cooper retweetledi
Chris Parker
Chris Parker@PCaParker·
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study - The Lancet Oncology thelancet.com/journals/lanon…
English
0
21
47
4.2K
S.Cooper retweetledi
Alison Tree 💙
Alison Tree 💙@alison_tree·
Fantastic work by the amazing Anna Wilkins and Sarah Stewart @EmmaHall71 #GU26 on the CHHiP trial, with long follow up. MMAI highly prognostic, as previously shown by @DrSpratticus and others across multiple trials
Emre Yekedüz@yekeduz_emre

CHHiP external validation of ArteraAI MMAI at @ASCO #GU26 In 1797 pts with localized PCa (median FU 14.3y), high MMAI strongly predicted BCR (HR 5.07) and was also associated with distant metastasis. Adding MMAI to CPG/NCCN models significantly improved discrimination (C-index) and model fit. AI-based pathology may refine risk stratification beyond standard clinicopathologic criteria. #prostatecancer #Cancer #Oncology @DrChoueiri @Silke_Gillessen @montypal @MikeSerzanMD @CParkMD @BraunMDPhD @OncBrothers @OncoAlert @OncLive @DrYukselUrun @nataliagandur @neerajaiims @DrRanaMcKay

English
1
2
25
2.5K
S.Cooper retweetledi
Piet Ost
Piet Ost@piet_ost·
The largest IPD meta-analysis of metastasis-directed therapy in prostate cancer. The magnitude of the benefit seems to be consistent on all the endpoints. Thanks @ChadTangMD for this amazing effort!
Chad Tang, MD@ChadTangMD

Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT65EIIgTS…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

English
2
7
33
4.6K
S.Cooper retweetledi
Advances, an ASTRO Journal
Advances, an ASTRO Journal@Advances_ASTRO·
Looking for guidance on adding direct-to-unit☢️ into your practice? Check out the recent consensus recommendations on implementing direct-to-unit palliative RT (PRT). Using a modified Delphi process, authors recommend: 🔘Diagnostic CT-based planning is appropriate for palliative intent tx (not curative tx, SBRT, mobile tumors) 🔘Diagnostic CT planning is NOT recommended when thermoplastic mask immobilization is indicated 🔘Scans used for planning should ideally be <72 H old; up to 2 weeks old is reasonable 🔘Conventional PRT dosing is appropriate for direct-to-unit planning (30/10, 20/5, 8/1); hypofx and SBRT is recommended 🔘Tx technique: 2D/3D is appropriate; IMRT/VMAT is generally not recommended Full recommendations can be found here: tinyurl.com/3979ucvm @ASTRO_org
Advances, an ASTRO Journal tweet media
English
0
13
18
2.1K

Keşfet

@TylerSbrt @SeibertLab @IJROBP @RO_GreenJournal @ARRO_org @ASTRO_org @ESTRO_org @alison_tree